Cheerful mid-stage depression drug data send Axsome stock flying
On the same day Sage rolled out $SAGE tremendous oral drug data in postpartum depression, Axsome Therapeutics has announced that its lead experimental CNS …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.